Answers are grounded in this paper and cite their sources.
Metabolic syndrome (MetS) is a growing concern in the context of chronic diseases, particularly among patients co-infected with HIV and sickle cell disease (SCD). This review aims to elucidate the prevalence, pathophysiology, and clinical implications of metabolic syndrome in HIV-infected sickle cell patients, a population that experiences unique challenges due to the interplay of these two conditions. Emerging evidence suggests that metabolic syndrome may exacerbate the complications associated with both HIV and SCD, leading to increased morbidity and mortality. The pathophysiological mechanisms underlying metabolic syndrome in this population are multifaceted, involving chronic inflammation, oxidative stress, and the metabolic effects of antiretroviral therapy (ART). These factors can contribute to insulin resistance, dyslipidemia, hypertension, and obesity, further complicating the management of both HIV and sickle cell disease. Understanding these interactions is critical for healthcare providers as they develop targeted strategies to monitor and manage metabolic syndrome, ensuring optimal patient care.
No takes yet. Share an insight, caveat, or question.
Obeagu et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: